Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study.
Judy N JacobseMichael SchaapveldNaomi B BoekelMaartje J HooningAgnes JagerMargreet H A BaaijensMichael HauptmannNicola S RussellEmiel J T RutgersBerthe M P AlemanGabe S SonkeFlora E van LeeuwenPublished in: Breast cancer research and treatment (2020)
Our results stress the importance of considering anthracycline-free regimens in BC patients who need trastuzumab-containing treatment. The association between aromatase inhibitors and HF needs confirmation.